Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on September 19, 2012. The report discloses a corporate governance event regarding the appointment and compensation of a senior officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Base Fee: $14,250 per month for the Acting Chief Financial Officer.
- Estimated Hours: 95 hours per month.
- Overtime Rate: $150 per hour for hours worked in excess of 95 per month.
- Benefits: The consultant is not eligible for employee pension, health, or other benefit plans.
Material Changes
On September 19, 2012, the Company entered into a new Independent Consulting Agreement with Thomas A. McGauley. This agreement:
- Extends his role as Acting Chief Financial Officer through December 31, 2012.
- Supersedes the previous consulting agreement filed on March 5, 2012.
- Becomes effective on October 1, 2012.
- Includes a provision for month-to-month extension at the sole discretion of the CEO.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The primary contingency noted is the temporary nature of the CFO role, which is subject to extension only at the CEO's discretion.
Investor Verification Checklist
- Verify the total compensation cost for the Acting CFO for the remainder of 2012 based on the $14,250 monthly rate.
- Confirm whether the Company has initiated a search for a permanent Chief Financial Officer.
- Review the attached Exhibit 10.1 for any additional termination clauses or non-compete provisions not summarized in the text.
- Check subsequent filings to determine if the consulting agreement was extended beyond December 31, 2012.